- Aptinyx Inc APTX has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and dementia with Lewy bodies.
- Aptinyx will release the data from this study in the second half of 2022.
- The screening was halted due to COVID-19 related restrictions.
- The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled study conducted in approximately 100 patients.
- The study will evaluate the overall safety and tolerability of NYX-458 30 mg daily oral dosing compared to placebo over 12 weeks.
- NYX-458 is a novel oral NMDA receptor modulator.
- Price Action: APTX shares jump 9.01% higher at $3.51 in the premarket trading on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
